Drugs in Dev. Immunology
Phase IV
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tepezza (teprotumumab-trbw) binds to insulin-like growth factor-1 receptor (IGF-1R) and blocks its activation and signaling. It is being investigated in patients with thyroid eye disease.
Product Name : Tepezza
Product Type : Antibody
Upfront Cash : Inapplicable
October 04, 2023
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Organon
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HADLIMA (Adalimumab-bwwd) is a biosimilar product of HUMIRA®, formulated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritisetc. The drug bind specifically to TNF-alpha and block its interaction with the p55 and p...
Product Name : Hadlima
Product Type : Antibody
Upfront Cash : Inapplicable
January 08, 2023
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Organon
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Guselkumab
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TREMFYA (guselkumab) is a fully human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is an important driver of the pathogenesis of inflammatory diseases.
Product Name : Tremfya
Product Type : Antibody
Upfront Cash : Inapplicable
October 11, 2022
Lead Product(s) : Guselkumab
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tepezza, (teprotumumab-trbw) first medicine approved by FDA for treatment of TED, among thousands of patients included in this 19-month new post-marketing Safety analysis, approximately 10% of all cases reported to safety database have included a hearing...
Product Name : Tepezza
Product Type : Antibody
Upfront Cash : Inapplicable
February 15, 2022
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Baricitinib
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Among those treated with OLUMIANT, the overall incidence rate of adverse events per 100 patient years of exposure was 22.6, and the incidence rate of serious adverse events was 7.4. Incidence rates remained stable over time across the 14,744 patient year...
Product Name : Olumiant
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2021
Lead Product(s) : Baricitinib
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Health Canada is informing Canadians and health care professionals that it is conducting a safety review of Xeljanz and Xeljanz XR (tofacitinib) after a clinical trial identified an increased risk of serious heart-related issues and cancer in trial parti...
Product Name : Xeljanz
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 04, 2021
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The co-primary endpoints of this study were non-inferiority of tofacitinib compared to TNFi in regard to major adverse cardiovascular events (MACE) and malignancies (excluding non-melanoma skin cancer (NMSC)).
Product Name : Xeljanz
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2021
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Teprotumumab,rHuPH20
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Horizon Pharma Plc
Deal Size : $190.0 million
Deal Type : Collaboration
Details : Horizon intends to use ENHANZE® to develop a SC formulation of TEPEZZA (teprotumumab-trbw), indicated for the treatment of Thyroid Eye Disease.
Product Name : Tepezza
Product Type : Antibody
Upfront Cash : $30.0 million
November 23, 2020
Lead Product(s) : Teprotumumab,rHuPH20
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Horizon Pharma Plc
Deal Size : $190.0 million
Deal Type : Collaboration
Reset All
